\select@language {UKenglish}
\select@language {UKenglish}
\contentsline {chapter}{Acronyms}{xvii}{section*.4}
\contentsline {chapter}{\numberline {1}Introduction and Literature Review}{1}{chapter.1}
\contentsline {section}{\numberline {1.1}Cancer Research in the Post-Genomic Era}{1}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Cancer is a Global Health Issue}{2}{subsection.1.1.1}
\contentsline {subsubsection}{\numberline {1.1.1.1}The Genetics and Molecular Biology of Cancers}{3}{subsubsection.1.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}The Genomics Revolution in Cancer Research}{3}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}High-Throughput Technologies}{4}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Bioinformatics and Genomic Data}{5}{subsubsection.1.1.2.2}
\contentsline {subsection}{\numberline {1.1.3}Genomics Projects}{5}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}The Cancer Genome Project}{6}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}The Cancer Genome Atlas Project}{6}{subsubsection.1.1.3.2}
\contentsline {subsection}{\numberline {1.1.4}Genomic Cancer Medicine}{8}{subsection.1.1.4}
\contentsline {subsubsection}{\numberline {1.1.4.1}Cancer Genes and Driver Mutations}{8}{subsubsection.1.1.4.1}
\contentsline {subsubsection}{\numberline {1.1.4.2}Precision Cancer Medicine}{9}{subsubsection.1.1.4.2}
\contentsline {subsubsection}{\numberline {1.1.4.3}Molecular Diagnostics and Pan-Cancer Medicine}{9}{subsubsection.1.1.4.3}
\contentsline {subsubsection}{\numberline {1.1.4.4}Targeted Therapeutics and Pharmacogenomics}{10}{subsubsection.1.1.4.4}
\contentsline {subsection}{\numberline {1.1.5}Systems and Network Biology}{11}{subsection.1.1.5}
\contentsline {section}{\numberline {1.2}Synthetic Lethal Cancer Medicine}{12}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Synthetic Lethal Genetic Interactions}{12}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Synthetic Lethal Concepts in Genetics}{14}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Synthetic Lethality in Model Systems}{14}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Synthetic Lethal Pathways and Networks}{15}{subsubsection.1.2.3.1}
\contentsline {subsubsection}{\numberline {1.2.3.2}Evolution of Synthetic Lethality}{15}{subsubsection.1.2.3.2}
\contentsline {subsection}{\numberline {1.2.4}Synthetic Lethality in Cancer}{16}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}Clinical Impact of Synthetic Lethality in Cancer}{18}{subsection.1.2.5}
\contentsline {subsection}{\numberline {1.2.6}High{}-throughput Screening for Synthetic Lethality}{19}{subsection.1.2.6}
\contentsline {subsubsection}{\numberline {1.2.6.1}Synthetic Lethal Screens}{21}{subsubsection.1.2.6.1}
\contentsline {subsection}{\numberline {1.2.7}Computational Prediction of Synthetic Lethality}{22}{subsection.1.2.7}
\contentsline {subsubsection}{\numberline {1.2.7.1}Bioinformatics Approaches to Genetic Interactions}{22}{subsubsection.1.2.7.1}
\contentsline {subsubsection}{\numberline {1.2.7.2}Comparative Genomics}{23}{subsubsection.1.2.7.2}
\contentsline {subsubsection}{\numberline {1.2.7.3}Analysis and Modelling of Protein Data}{26}{subsubsection.1.2.7.3}
\contentsline {subsubsection}{\numberline {1.2.7.4}Differential Gene Expression}{27}{subsubsection.1.2.7.4}
\contentsline {subsubsection}{\numberline {1.2.7.5}Data Mining and Machine Learning}{28}{subsubsection.1.2.7.5}
\contentsline {subsubsection}{\numberline {1.2.7.6}Mutual Exclusivity and Bimodality}{31}{subsubsection.1.2.7.6}
\contentsline {subsubsection}{\numberline {1.2.7.7}Rationale for Further Development}{32}{subsubsection.1.2.7.7}
\contentsline {section}{\numberline {1.3}E-cadherin as a Synthetic Lethal Target}{33}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}The \textit {CDH1} gene and its Biological Functions}{33}{subsection.1.3.1}
\contentsline {subsection}{\numberline {1.3.2}Hereditary Diffuse Gastric (and Lobular Breast) Cancer}{34}{subsection.1.3.2}
\contentsline {subsection}{\numberline {1.3.3}Cell Line Models of \textit {CDH1} Null Mutations}{35}{subsection.1.3.3}
\contentsline {section}{\numberline {1.4}Summary and Research Direction of Thesis}{35}{section.1.4}
\contentsline {subsection}{\numberline {1.4.1}Thesis Aims}{36}{subsection.1.4.1}
\contentsline {chapter}{\numberline {2}Methods and Resources}{38}{chapter.2}
\contentsline {section}{\numberline {2.1}Bioinformatics Resources for Genomics Research}{38}{section.2.1}
\contentsline {subsection}{\numberline {2.1.1}Public Data and Software Packages}{38}{subsection.2.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.1}Cancer Genome Atlas Data}{39}{subsubsection.2.1.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.2}Reactome and Annotation Data}{40}{subsubsection.2.1.1.2}
\contentsline {section}{\numberline {2.2}Data Handling}{40}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Normalisation}{40}{subsection.2.2.1}
\contentsline {subsection}{\numberline {2.2.2}Sample Triage}{40}{subsection.2.2.2}
\contentsline {subsection}{\numberline {2.2.3}Metagenes and the Singular Value Decomposition}{41}{subsection.2.2.3}
\contentsline {subsection}{\numberline {2.2.4}Candidate Triage and Integration with Screen Data}{43}{subsection.2.2.4}
\contentsline {section}{\numberline {2.3}Techniques}{43}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Statistical Procedures and Tests}{44}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Gene Set Over-representation Analysis}{45}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}Clustering}{45}{subsection.2.3.3}
\contentsline {subsection}{\numberline {2.3.4}Heatmap}{45}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}Modelling and Simulations}{46}{subsection.2.3.5}
\contentsline {subsubsection}{\numberline {2.3.5.1}Receiver Operating Characteristic Curves}{47}{subsubsection.2.3.5.1}
\contentsline {subsection}{\numberline {2.3.6}Resampling Analysis}{47}{subsection.2.3.6}
\contentsline {section}{\numberline {2.4}Pathway Structure Methods}{48}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Network and Graph Analysis}{48}{subsection.2.4.1}
\contentsline {subsection}{\numberline {2.4.2}Sourcing Graph Structure Data}{49}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Constructing Pathway Subgraphs}{49}{subsection.2.4.3}
\contentsline {subsection}{\numberline {2.4.4}Network Analysis Metrics}{50}{subsection.2.4.4}
\contentsline {section}{\numberline {2.5}Implementation}{51}{section.2.5}
\contentsline {subsection}{\numberline {2.5.1}Computational Resources and Linux Utilities}{51}{subsection.2.5.1}
\contentsline {subsection}{\numberline {2.5.2}R Language and Packages}{52}{subsection.2.5.2}
\contentsline {subsection}{\numberline {2.5.3}High Performance and Parallel Computing}{55}{subsection.2.5.3}
\contentsline {chapter}{\numberline {3}Methods Developed During Thesis}{57}{chapter.3}
\contentsline {section}{\numberline {3.1}A Synthetic Lethal Detection Methodology}{57}{section.3.1}
\contentsline {section}{\numberline {3.2}Synthetic Lethal Simulation and Modelling}{59}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}A Model of Synthetic Lethality in Expression Data}{60}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Simulation Procedure}{64}{subsection.3.2.2}
\contentsline {section}{\numberline {3.3}Detecting Simulated Synthetic Lethal Partners}{67}{section.3.3}
\contentsline {subsection}{\numberline {3.3.1}Binomial Simulation of Synthetic Lethality}{67}{subsection.3.3.1}
\contentsline {subsection}{\numberline {3.3.2}Multivariate Normal Simulation of Synthetic Lethality}{69}{subsection.3.3.2}
\contentsline {subsubsection}{\numberline {3.3.2.1}Multivariate Normal Simulation with Correlated Genes}{71}{subsubsection.3.3.2.1}
\contentsline {subsubsection}{\numberline {3.3.2.2}Specificity with Query-Correlated Pathways}{79}{subsubsection.3.3.2.2}
\contentsline {section}{\numberline {3.4}Graph Structure Methods}{81}{section.3.4}
\contentsline {subsection}{\numberline {3.4.1}Upstream and Downstream Gene Detection}{81}{subsection.3.4.1}
\contentsline {subsubsection}{\numberline {3.4.1.1}Permutation Analysis for Statistical Significance}{82}{subsubsection.3.4.1.1}
\contentsline {subsection}{\numberline {3.4.2}Simulating Gene Expression from Graph Structures}{83}{subsection.3.4.2}
\contentsline {section}{\numberline {3.5}Customised Functions and Packages Developed}{87}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Synthetic Lethal Interaction Prediction Tool}{87}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Data Visualisation}{88}{subsection.3.5.2}
\contentsline {subsection}{\numberline {3.5.3}Extensions to the iGraph Package}{89}{subsection.3.5.3}
\contentsline {subsubsection}{\numberline {3.5.3.1}Sampling Simulated Data from Graph Structures}{89}{subsubsection.3.5.3.1}
\contentsline {subsubsection}{\numberline {3.5.3.2}Plotting Directed Graph Structures}{89}{subsubsection.3.5.3.2}
\contentsline {subsubsection}{\numberline {3.5.3.3}Computing Information Centrality}{91}{subsubsection.3.5.3.3}
\contentsline {subsubsection}{\numberline {3.5.3.4}Testing Pathway Structure with Permutation Testing}{91}{subsubsection.3.5.3.4}
\contentsline {subsubsection}{\numberline {3.5.3.5}Metapackage to Install iGraph Functions}{92}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {4}Synthetic Lethal Analysis of Gene Expression Data}{93}{chapter.4}
\contentsline {section}{\numberline {4.1}Synthetic Lethal Genes in Breast Cancer}{94}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Synthetic Lethal Pathways in Breast Cancer}{95}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Expression Profiles of Synthetic Lethal Partners}{97}{subsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.2.1}Subgroup Pathway Analysis}{100}{subsubsection.4.1.2.1}
\contentsline {section}{\numberline {4.2}Comparing Synthetic Lethal Gene Candidates}{102}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Primary siRNA Screen Candidates}{102}{subsection.4.2.1}
\contentsline {subsection}{\numberline {4.2.2}Comparison with Correlation}{102}{subsection.4.2.2}
\contentsline {subsection}{\numberline {4.2.3}Comparison with Primary Screen Viability}{105}{subsection.4.2.3}
\contentsline {subsection}{\numberline {4.2.4}Comparison with Secondary siRNA Screen Validation}{107}{subsection.4.2.4}
\contentsline {subsection}{\numberline {4.2.5}Comparison to Primary Screen at Pathway Level}{108}{subsection.4.2.5}
\contentsline {subsubsection}{\numberline {4.2.5.1}Resampling Genes for Pathway Enrichment}{110}{subsubsection.4.2.5.1}
\contentsline {subsection}{\numberline {4.2.6}Integrating Synthetic Lethal Pathways and Screens}{115}{subsection.4.2.6}
\contentsline {section}{\numberline {4.3}Synthetic Lethal Pathway Metagenes}{116}{section.4.3}
\contentsline {section}{\numberline {4.4}Replication in Stomach Cancer}{118}{section.4.4}
\contentsline {section}{\numberline {4.5}Discussion}{119}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Strengths of the SLIPT Methodology}{119}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Synthetic Lethal Pathways for E-cadherin}{120}{subsection.4.5.2}
\contentsline {subsection}{\numberline {4.5.3}Replication and Validation}{122}{subsection.4.5.3}
\contentsline {subsubsection}{\numberline {4.5.3.1}Integration with siRNA Screening}{122}{subsubsection.4.5.3.1}
\contentsline {subsubsection}{\numberline {4.5.3.2}Replication across Tissues}{123}{subsubsection.4.5.3.2}
\contentsline {section}{\numberline {4.6}Summary}{123}{section.4.6}
\contentsline {chapter}{\numberline {5}Synthetic Lethal Pathway Structure}{125}{chapter.5}
\contentsline {section}{\numberline {5.1}Synthetic Lethal Genes in Reactome Pathways}{125}{section.5.1}
\contentsline {subsection}{\numberline {5.1.1}The PI3K/AKT Pathway}{126}{subsection.5.1.1}
\contentsline {subsection}{\numberline {5.1.2}The Extracellular Matrix}{128}{subsection.5.1.2}
\contentsline {subsection}{\numberline {5.1.3}G Protein Coupled Receptors}{129}{subsection.5.1.3}
\contentsline {subsection}{\numberline {5.1.4}Gene Regulation and Translation}{129}{subsection.5.1.4}
\contentsline {section}{\numberline {5.2}Network Analysis of Synthetic Lethal Genes}{131}{section.5.2}
\contentsline {subsection}{\numberline {5.2.1}Gene Connectivity and Vertex Degree}{131}{subsection.5.2.1}
\contentsline {subsection}{\numberline {5.2.2}Gene Importance and Centrality}{133}{subsection.5.2.2}
\contentsline {subsubsection}{\numberline {5.2.2.1}Information Centrality}{133}{subsubsection.5.2.2.1}
\contentsline {subsubsection}{\numberline {5.2.2.2}PageRank Centrality}{134}{subsubsection.5.2.2.2}
\contentsline {section}{\numberline {5.3}Relationships between Synthetic Lethal Genes}{136}{section.5.3}
\contentsline {subsection}{\numberline {5.3.1}Detecting Upstream or Downstream Synthetic Lethality}{136}{subsection.5.3.1}
\contentsline {subsection}{\numberline {5.3.2}Resampling for Synthetic Lethal Pathway Structure}{139}{subsection.5.3.2}
\contentsline {section}{\numberline {5.4}Discussion}{140}{section.5.4}
\contentsline {section}{\numberline {5.5}Summary}{142}{section.5.5}
\contentsline {chapter}{\numberline {6}Simulation and Modelling of Synthetic Lethal Pathways}{144}{chapter.6}
\contentsline {section}{\numberline {6.1}Synthetic Lethal Detection Methods}{145}{section.6.1}
\contentsline {subsection}{\numberline {6.1.1}Performance of SLIPT and $\chi ^2$ across Quantiles}{145}{subsection.6.1.1}
\contentsline {subsubsection}{\numberline {6.1.1.1}Correlated Query Genes affects Specificity}{149}{subsubsection.6.1.1.1}
\contentsline {subsection}{\numberline {6.1.2}Alternative Synthetic Lethal Detection Strategies}{150}{subsection.6.1.2}
\contentsline {subsubsection}{\numberline {6.1.2.1}Correlation for Synthetic Lethal Detection}{151}{subsubsection.6.1.2.1}
\contentsline {subsubsection}{\numberline {6.1.2.2}Testing for Bimodality with BiSEp}{152}{subsubsection.6.1.2.2}
\contentsline {section}{\numberline {6.2}Simulations with Graph structures}{153}{section.6.2}
\contentsline {subsection}{\numberline {6.2.1}Performance over Graph structures}{154}{subsection.6.2.1}
\contentsline {subsubsection}{\numberline {6.2.1.1}Simple Graph structures}{154}{subsubsection.6.2.1.1}
\contentsline {subsubsection}{\numberline {6.2.1.2}Constructed Graph structures}{155}{subsubsection.6.2.1.2}
\contentsline {subsection}{\numberline {6.2.2}Performance with Inhibitions}{158}{subsection.6.2.2}
\contentsline {subsection}{\numberline {6.2.3}Synthetic Lethality across Graph structures}{163}{subsection.6.2.3}
\contentsline {subsection}{\numberline {6.2.4}Performance within a Large Simulated Dataset}{166}{subsection.6.2.4}
\contentsline {section}{\numberline {6.3}Simulations in More Complex Graph structures}{169}{section.6.3}
\contentsline {subsection}{\numberline {6.3.1}Simulations over Pathway-based Graphs}{170}{subsection.6.3.1}
\contentsline {subsection}{\numberline {6.3.2}Pathway Structures in a Large Simulated Dataset}{173}{subsection.6.3.2}
\contentsline {section}{\numberline {6.4}Discussion}{175}{section.6.4}
\contentsline {subsection}{\numberline {6.4.1}Simulation Procedure}{175}{subsection.6.4.1}
\contentsline {subsection}{\numberline {6.4.2}Comparing Methods with Simulated Data}{176}{subsection.6.4.2}
\contentsline {subsection}{\numberline {6.4.3}Design and Performance of SLIPT}{177}{subsection.6.4.3}
\contentsline {subsection}{\numberline {6.4.4}Simulations from Graph structures}{179}{subsection.6.4.4}
\contentsline {section}{\numberline {6.5}Summary}{180}{section.6.5}
\contentsline {chapter}{\numberline {7}Discussion}{182}{chapter.7}
\contentsline {section}{\numberline {7.1}Synthetic Lethality and \textit {CDH1} Biology}{182}{section.7.1}
\contentsline {subsection}{\numberline {7.1.1}Established Functions of \textit {CDH1}}{183}{subsection.7.1.1}
\contentsline {subsection}{\numberline {7.1.2}The Molecular Role of \textit {CDH1} in Cancer}{183}{subsection.7.1.2}
\contentsline {section}{\numberline {7.2}Significance}{184}{section.7.2}
\contentsline {subsection}{\numberline {7.2.1}Synthetic Lethality in the Genomic Era}{184}{subsection.7.2.1}
\contentsline {subsection}{\numberline {7.2.2}Clinical Interventions based on Synthetic Lethality}{186}{subsection.7.2.2}
\contentsline {section}{\numberline {7.3}Future Directions}{187}{section.7.3}
\contentsline {section}{\numberline {7.4}Conclusions}{189}{section.7.4}
\contentsline {chapter}{\hbox to\@tempdima {\hfil }Bibliography}{191}{section.7.4}
\contentsline {chapter}{\numberline {A}Sample Quality}{215}{appendix.A}
\contentsline {section}{\numberline {A.1}Sample Correlation}{215}{section.A.1}
\contentsline {section}{\numberline {A.2}Replicate Samples in TCGA Breast Cancer Data}{217}{section.A.2}
\contentsline {chapter}{\numberline {B}Software Used for Thesis}{221}{appendix.B}
\contentsline {chapter}{\numberline {C}Mutation Analysis in Breast Cancer}{230}{appendix.C}
\contentsline {section}{\numberline {C.1}Synthetic Lethal Genes and Pathways}{230}{section.C.1}
\contentsline {section}{\numberline {C.2}Synthetic Lethal Expression Profiles}{233}{section.C.2}
\contentsline {section}{\numberline {C.3}Comparison to Primary Screen}{236}{section.C.3}
\contentsline {subsection}{\numberline {C.3.1}Resampling Analysis}{238}{subsection.C.3.1}
\contentsline {section}{\numberline {C.4}Compare SLIPT genes}{240}{section.C.4}
\contentsline {chapter}{\numberline {D}Metagene Analysis}{242}{appendix.D}
\contentsline {section}{\numberline {D.1}Pathway Signature Expression}{242}{section.D.1}
\contentsline {section}{\numberline {D.2}Synthetic Lethal Reactome Metagenes}{246}{section.D.2}
\contentsline {chapter}{\numberline {E}Intrinsic Subtyping}{247}{appendix.E}
\contentsline {chapter}{\numberline {F}Stomach Expression Analysis}{249}{appendix.F}
\contentsline {section}{\numberline {F.1}Synthetic Lethal Genes and Pathways}{249}{section.F.1}
\contentsline {section}{\numberline {F.2}Comparison to Primary Screen}{253}{section.F.2}
\contentsline {subsection}{\numberline {F.2.1}Resampling Analysis}{255}{subsection.F.2.1}
\contentsline {section}{\numberline {F.3}Metagene Analysis}{257}{section.F.3}
\contentsline {chapter}{\numberline {G}Synthetic Lethal Genes in Pathways}{258}{appendix.G}
\contentsline {chapter}{\numberline {H}Network Analysis for Mutation SLIPT}{267}{appendix.H}
\contentsline {chapter}{\numberline {I}Pathway Structure for Mutation SLIPT}{270}{appendix.I}
\contentsline {chapter}{\numberline {J}Performance of SLIPT and $\chi ^2$}{272}{appendix.J}
\contentsline {section}{\numberline {J.1}Correlated Query Genes affects Specificity}{278}{section.J.1}
\contentsline {chapter}{\numberline {K}Simulations on Graph Structures}{284}{appendix.K}
\contentsline {section}{\numberline {K.1}Simulations from Inhibiting Graph Structures}{285}{section.K.1}
\contentsline {section}{\numberline {K.2}Simulation across Graph Structures}{288}{section.K.2}
\contentsline {section}{\numberline {K.3}Simulations within a Large Simulated Dataset}{292}{section.K.3}
\contentsline {section}{\numberline {K.4}Simulations from Complex Graph Structures}{293}{section.K.4}
\contentsline {section}{\numberline {K.5}Simulations from Complex Inhibiting Graphs}{296}{section.K.5}
\contentsline {section}{\numberline {K.6}Simulations from Pathway Graph Structures}{302}{section.K.6}
